These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8365472)

  • 1. The in situ degradation of ceramide, a potential lipid mediator, is not completely impaired in Farber disease.
    Levade T; Tempesta MC; Salvayre R
    FEBS Lett; 1993 Aug; 329(3):306-12. PubMed ID: 8365472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulfatide and sphingomyelin loading of living cells as tools for the study of ceramide turnover by lysosomal ceramidase--implications for the diagnosis of Farber disease.
    Levade T; Tempesta MC; Moser HW; Fensom AH; Harzer K; Moser AB; Salvayre R
    Biochem Mol Med; 1995 Apr; 54(2):117-25. PubMed ID: 8581356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurodegenerative course in ceramidase deficiency (Farber disease) correlates with the residual lysosomal ceramide turnover in cultured living patient cells.
    Levade T; Moser HW; Fensom AH; Harzer K; Moser AB; Salvayre R
    J Neurol Sci; 1995 Dec; 134(1-2):108-14. PubMed ID: 8747852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism of ceramide-containing endocytotic vesicles in human diploid fibroblasts.
    Sutrina SL; Chen WW
    J Biol Chem; 1982 Mar; 257(6):3039-44. PubMed ID: 7061463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Turnover of endogenous ceramide in cultured normal and Farber fibroblasts.
    van Echten-Deckert G; Klein A; Linke T; Heinemann T; Weisgerber J; Sandhoff K
    J Lipid Res; 1997 Dec; 38(12):2569-79. PubMed ID: 9458280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural ceramide is unable to escape the lysosome, in contrast to a fluorescent analogue.
    Chatelut M; Leruth M; Harzer K; Dagan A; Marchesini S; Gatt S; Salvayre R; Courtoy P; Levade T
    FEBS Lett; 1998 Apr; 426(1):102-6. PubMed ID: 9598987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In situ assay of acid sphingomyelinase and ceramidase based on LDL-mediated lysosomal targeting of ceramide-labeled sphingomyelin.
    Levade T; Leruth M; Graber D; Moisand A; Vermeersch S; Salvayre R; Courtoy PJ
    J Lipid Res; 1996 Dec; 37(12):2525-38. PubMed ID: 9017505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simple method for screening for Farber disease on cultured skin fibroblasts.
    Chatelut M; Feunteun J; Harzer K; Fensom AH; Basile JP; Salvayre R; Levade T
    Clin Chim Acta; 1996 Feb; 245(1):61-71. PubMed ID: 8646815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceramide accumulation is associated with increased apoptotic cell death in cultured fibroblasts of sphingolipid activator protein-deficient mouse but not in fibroblasts of patients with Farber disease.
    Tohyama J; Oya Y; Ezoe T; Vanier MT; Nakayasu H; Fujita N; Suzuki K
    J Inherit Metab Dis; 1999 Jun; 22(5):649-62. PubMed ID: 10399097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysosomal involvement in cellular turnover of plasma membrane sphingomyelin.
    Sutrina SL; Chen WW
    Biochim Biophys Acta; 1984 Apr; 793(2):169-79. PubMed ID: 6424713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model SV40-transformed fibroblast lines for metabolic studies of human prosaposin and acid ceramidase deficiencies.
    Chatelut M; Harzer K; Christomanou H; Feunteun J; Pieraggi MT; Paton BC; Kishimoto Y; O'Brien JS; Basile JP; Thiers JC; Salvayre R; Levade T
    Clin Chim Acta; 1997 Jun; 262(1-2):61-76. PubMed ID: 9204210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substrate-specificities of acid and alkaline ceramidases in fibroblasts from patients with Farber disease and controls.
    Momoi T; Ben-Yoseph Y; Nadler HL
    Biochem J; 1982 Aug; 205(2):419-25. PubMed ID: 6814427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stress-induced apoptosis is not mediated by endolysosomal ceramide.
    Ségui B; Bezombes C; Uro-Coste E; Medin JA; Andrieu-Abadie N; Augé N; Brouchet A; Laurent G; Salvayre R; Jaffrézou JP; Levade T
    FASEB J; 2000 Jan; 14(1):36-47. PubMed ID: 10627278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Farber's lipogranulomatosis].
    Koga M
    Nihon Rinsho; 1995 Dec; 53(12):3009-13. PubMed ID: 8577050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-trimester enzyme exclusion of Farber disease using a micromethod with [3H]ceramide.
    Akhunov VS; Gargaun SS; Krasnopolskaya XD
    J Inherit Metab Dis; 1995; 18(5):616-9. PubMed ID: 8598643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of lysosomal acid ceramidase in the metabolism of ceramide in human skin fibroblasts.
    Chen WW; Moser AB; Moser HW
    Arch Biochem Biophys; 1981 May; 208(2):444-55. PubMed ID: 7259198
    [No Abstract]   [Full Text] [Related]  

  • 17. Abnormalities of lysosomes in human diploid fibroblasts from patients with Farber's disease.
    Chen WW; Decker GL
    Biochim Biophys Acta; 1982 Oct; 718(2):185-92. PubMed ID: 6814495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Farber disease [Farber lipogranulomatosis], acid ceramidase deficiency].
    Koga M
    Ryoikibetsu Shokogun Shirizu; 1998; (19 Pt 2):389-93. PubMed ID: 9645089
    [No Abstract]   [Full Text] [Related]  

  • 19. Retrovirus-mediated correction of the metabolic defect in cultured Farber disease cells.
    Medin JA; Takenaka T; Carpentier S; Garcia V; Basile JP; Segui B; Andrieu-Abadie N; Auge N; Salvayre R; Levade T
    Hum Gene Ther; 1999 May; 10(8):1321-9. PubMed ID: 10365663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farber disease: pathologic diagnosis in sibs with phenotypic variability.
    Qualman SJ; Moser HW; Valle D; Moser AE; Antonarakis SE; Boitnott JK; Zinkham WH
    Am J Med Genet Suppl; 1987; 3():233-41. PubMed ID: 3130860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.